Follicular Lymphoma Patients and Caregivers: Thank You!
Lymphoma Canada is preparing a submission to the panCanadian Oncology Drug Review (pCODR) for:
- Idelalisib (Zydelig) for the treatment of patients with follicular lymphoma who have received at least two prior systemic regimens and are refractory to both rituximab and an alkylating agent.
Thank you to all the patients and caregivers who helped by completing our surveys!
THE SURVEYS ARE NOW CLOSED.